ArticleCureus2022
Treatment of Hematomas Using a Synthetic Hybrid-Scale Fiber Matrix.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- Novel Use of a Synthetic Electrospun Wound Matrix in an Extensive Forearm Degloving Injury: Case Report and Review of the Literature.Plastic and reconstructive surgery. Global open · 2025Article
- Utility of a Synthetic Hybrid-Scale Fiber Matrix in Surgical Soft Tissue Reconstruction.Eplasty · 2024Article
- Management of irradiated post-mastectomy wound dehiscence with synthetic electrospun fiber matrix: a case report.Frontiers in oncology · 2024Article
- A debriding gel in the treatment of post-trauma, non-healing lesions.International journal of burns and trauma · 2023Article
- Clinical Application of Bioresorbable, Synthetic, Electrospun Matrix in Wound Healing.Bioengineering (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective treatment of traumatic subcutaneous hematomas is important to avoid complications, including skin necrosis, infection, scarring, hyperpigmentation, tissue edema, and prolonged recovery. Hematoma treatment may include evacuation followed by application of a skin substitute. Given the challenges associated with conventional skin substitutes, a fully-synthetic, resorbable, electrospun matrix composed of hybrid-scale fibers may offer a new option for treating hematomas. The present study reports on two clinical case reports assessing the use of the synthetic hybrid-scale fiber matrix for the treatment of hematomas. The hematomas located on the pretibial leg and dorsal foot were debrided in the operating room with evacuation of the hematomas, and the synthetic matrix was applied to the wounds. Following treatment, the wounds were observed for healing progress, including measuring and photographing the wounds and documenting clinical observations. The synthetic hybrid-scale fiber matrix was re-applied as needed based on clinician discretion. In both cases, treatment following the use of the synthetic hybrid-scale fiber matrix resulted in complete healing. Complete closure of all wounds was observed after two to three applications of the synthetic matrix within six to 16 weeks, and no adverse events were noted. In this study, hematomas of the foot and the leg demonstrated successful healing following treatment with the synthetic hybrid-scale fiber matrix. The successful clinical outcomes suggest that this biomaterial may offer benefits as part of a new treatment paradigm for hematomas and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.